Board Member
Roivant Sciences Ltd. (ROIV)Equibles does not estimate personal net worth.
Get an email with a short summary when Roivant Sciences Ltd. publishes a filing, an earnings call transcript or a press release.
Get ROIV alertsMatthew Gline is recorded as CEO and Board Member at Roivant Sciences Ltd. (ROIV). The newest filing on record that lists Matthew Gline as CEO and Board Member at Roivant Sciences Ltd. (ROIV) is dated July 29, 2026. The proxy statement of Roivant Sciences Ltd. reports total compensation of $3,096,190 for Matthew Gline in fiscal 2025, including a base salary of $725,000. Disclosed compensation is on record for 6 fiscal years. Matthew Gline has spoken on 9 earnings calls across 1 company, most recently for Roivant Sciences Ltd. on May 20, 2026. Roivant Sciences Ltd. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Roivant Sciences Ltd. includes Eric Venker (CEO and COO), Richard Pulik (CFO), Jennifer Humes (Chief Accounting Officer) and 7 others.
“So look, a lot to be excited about on the program here. I just want to, a couple quick reminders and a summary on slide 22 and 23 here. On slide 22, so Drew talked about this in detail, but just as a reminder, the primary endpoint of this study is PVR.”
“So not at all a quiet quarter for us; we put out both the Graves' data and, obviously, the Phase III data for brepocitinib in DM.”
“About a week ago, I discussed a draft of this morning's presentation with the team and thought it could be a rather dull 10-Q. After our Investor Day in December and the JPMorgan conference, we ended up with a very busy week.”
“This was not a quiet quarter for us, as we put out both the Graves' data and, obviously, the Phase III data for brepocitinib in dermatomyositis.”
“This quarter is relatively quiet, but we anticipate a busy fall. I look forward to sharing updates and addressing your questions. I will begin on Page 5 with a reminder of our position for this year.”
Start not stated–present
Last confirmed July 29, 2026
Start not stated–present
Last confirmed July 29, 2026
Biotechnology · Healthcare
CEO, Board Member
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Roivant Sciences Ltd. (ROIV) | Chief Executive Officer | $725,000 | $3,096,190 |
| 2024 | Roivant Sciences Ltd. (ROIV) | Chief Executive Officer | $725,000 | $163,293,744 |
| 2023 | Roivant Sciences Ltd. (ROIV) | Chief Executive Officer | $725,000 | $738,189 |
| 2022 | Roivant Sciences Ltd. (ROIV) | Chief Executive Officer | $725,000 | $48,978,825 |
| 2021 | Roivant Sciences Ltd. (ROIV) | Chief Executive Officer | $725,000 | $30,460,032 |
| 2020 | Roivant Sciences Ltd. (ROIV) | Chief Executive Officer | $350,000 | $8,310,550 |
